Streptococcus viridans group (2018 Data)
Antibiotic |
% Susceptible |
Antibiotic |
% Susceptible |
|
Ampicillin | 83 |
Imipenem | + |
|
Azithromycin | 44 |
Levofloxacin | 96 |
|
Aztreonam | -* |
Meropenem | 94 |
|
Cefazolin | + |
Moxifloxacin | +
|
|
Cefepime | 92 |
Nitrofurantoin | &
|
|
Ceftazidime | +/- |
Oxacillin/Naf | +- |
|
Ceftriaxone | 96 |
Penicillin | 88 |
|
Cefuroxime | + |
Piperacillin | +
|
|
Ciprofloxacin | +-* |
Piperacillin/tazo | + |
|
Clarithromycin | +-* |
Ticarcillin/Clav | + |
|
Clindamycin | 72 |
Tobramycin | -* |
|
Doxycycline | 58 |
TMP/SMX | + |
|
Erythromycin | 39 |
Unasyn/Aug | + |
|
Gentamicin | -* |
Vancomycin | 100 |
|
Number of isolates tested: 52
Comments:
For historical susceptibility data click here
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections